Targeted personalized medicines, nutritional solutions and longitudinal health monitoring will be based on differentiated “-omics” signatures, transcending todays “one size fits all” approach.
Personalized health signatures comprised of hundreds of data points will become the diagnostic reality of the future. Within these, robust multiparameter metabolite biomarkers will serve as the phenotype “dashboard” of our bioengines, allowing optimized tailoring of disease prophylaxis and therapeutic intervention.
